Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells

Cellular & Molecular Immunology volume 16, pages 621–624 (2019)Cite this article

Subjects

Splenic marginal zone lymphoma (SMZL) is an incurable indolent small B-cell lymphoma that primarily involves the spleen and arises in elderly patients, who have a median age of 65 years old at diagnosis.1 Splenomegaly is the most common clinical sign and is observed in 75% of patients. Peripheral blood infiltration of tumor B-cells is detected in approximately 60% of cases.2 Dissemination to the bone marrow is almost constantly found.3 The 5-year overall survival ranges from 67.8 to 81% depending on the clinical stage at diagnosis and treatment approach.4 Transformation to aggressive large B-cell lymphoma occurs in ~10% of SMZL cases by 12 years.5

Escape from immune control must be important in the long-term natural course of indolent B-cell lymphomas. The presence of PD-1-positive T-cells, a characteristic of tumors with an immune-inflamed phenotype, has been reported in marginal zone lymphomas.6 The immune-inflamed phenotype is associated with “high” intratumor T-cell content.7 This phenotype suggests the presence of a preexisting antitumor immune response that has been arrested, probably by local immunosuppression in the tumor bed. Other described immune tumor profiles are the immune-excluded phenotype and immune-desert phenotype. The immune-excluded phenotype is also characterized by the presence of abundant T-cells. However, these T-cells are located in the periphery as they are retained in the stroma that surrounds nests of tumor cells. The immune-desert phenotype is characterized by a paucity of T-cells in the tumor (for a review, see Chen et al.7).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Thieblemont, C. et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet. Oncol. 4, 95–103 (2003).

    Article  CAS  PubMed  Google Scholar 

  2. Berger, F. et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 95, 1950–1956 (2000).

    CAS  PubMed  Google Scholar 

  3. Petit, B. et al. Among 157 marginal zone lymphomas, DBA.44(CD76) expression is restricted to tumour cells infiltrating the red pulp of the spleen with a diffuse architectural pattern. Histopathology 54, 626–631 (2009).

    Article  PubMed  Google Scholar 

  4. Perrone, S. et al. Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. Leuk. Res. 44, 53–60 (2016).

    Article  PubMed  Google Scholar 

  5. Casulo, C. & Friedberg, J. Transformation of marginal zone lymphoma (and association with other lymphomas). Best. Pract. Res. Clin. Haematol. 30, 131–138 (2017).

    Article  PubMed  Google Scholar 

  6. Xu-Monette, Z. Y., Zhou, J. & Young, K. H. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131, 68–83 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).

    Article  CAS  PubMed  Google Scholar 

  8. Laurent, C. et al. Several immune escape patterns in non-Hodgkin’s lymphomas. Oncoimmunology 4, e1026530 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Nash, J. R. Macrophages in human tumours: an immunohistochemical study. J. Pathol. 136, 72–83 (1982).

    Article  CAS  PubMed  Google Scholar 

  10. Takahashi, K., Yamaguchi, H., Ishizeki, J., Nakajima, T. & Nakazato, Y. Immunohistochemical and immunoelectron microscopic localization of S-100 protein in the interdigitating reticulum cells of the human lymph node. Virchows. Arch. B. Cell Pathol. Incl. Mol. Pathol. 37, 125–135 (1981).

    Article  CAS  PubMed  Google Scholar 

  11. Udall, M. et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn. Pathol. 13, 12 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ionescu, D. N., Downes, M. R., Christofides, A. & Tsao, M. S. Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective. Curr. Oncol. Tor. Ont. 25, e209–e216 (2018).

    Article  CAS  Google Scholar 

  13. Andorsky, D. J. et al. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 17, 4232–4244 (2011).

    Article  CAS  Google Scholar 

  14. Panjwani, P. K. et al. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum. Pathol. 71, 91–99 (2018).

    Article  CAS  PubMed  Google Scholar 

  15. Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8+T-cell recruitment. Cancer Res. 69, 3077–3085 (2009).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr J Cook Moreau, UMR CNRS 7276, Limoges, France, for English editing. The group of J Feuillard is supported by grants from the Ligue Nationale Contre le Cancer (Equipe Labellisée Ligue), the Institut National Contre le Cancer (INCa), the Comité Orientation Recherche Cancer (CORC), the Limousin Region and the Haute Vienne and Corrèze committees of the Ligue Nationale Contre le Cancer and the Lyons Club of Corrèze.

Author contributions

C.V.F. and I.S. performed and analyzed the experiments and contributed to the writing. V.V. performed the TMA and immunohistochemistry. I.S. and M.P. contributed to SMZL diagnosis as well as to analyzing the immunohistochemistry results. R.J. and E.L. contributed to the labeling. N.G. performed the Affymetrix* gene expression profiles. J.F. and N.F. designed and directed the study, contributed to the experiments, analyzed the results and wrote the manuscript.

Author information

Author notes

  1. These authors equally contributed: Christelle Vincent-Fabert, Isabelle Soubeyran.

Authors and Affiliations

  1. CNRS-UMR 7276 INSERM U1262 CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France

    Christelle Vincent-Fabert, Robin Jeannet, Emilie Lereclus, Nathalie Gachard, Jean Feuillard & Nathalie Faumont

  2. Laboratory of Pathology, Institut Bergonié, Bordeaux, France

    Isabelle Soubeyran & Valérie Velasco

  3. Pathology Department, Hospital University Center of Bordeaux, Bordeaux, France

    Marie Parrens

Authors
  1. Christelle Vincent-Fabert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabelle Soubeyran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valérie Velasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marie Parrens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robin Jeannet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emilie Lereclus
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nathalie Gachard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean Feuillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nathalie Faumont
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathalie Faumont.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vincent-Fabert, C., Soubeyran, I., Velasco, V. et al. Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells. Cell Mol Immunol 16, 621–624 (2019). https://doi.org/10.1038/s41423-019-0228-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-019-0228-y

Search

Advanced search

Quick links